Skip to content
Open access

cGAS Downregulation Contributes to EGFR-TKI Resistance in NSCLC through the p-Nrf2–SIRT3–ROS/Ferroptosis Axis

Sep 2026 · Oncology Research · Vol 34, pp. 1-10 · 0 citations · 45 references
Medicine

TL;DR

Findings identify low cGAS abundance as a feature of the resistant state and support its involvement in an Nrf2–SIRT3-dependent antioxidant program that raises the threshold for ferroptotic damage.

Abstract

Background: Although epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibition produces substantial initial benefit in EGFR-mutant non-small cell lung cancer, durable disease control is frequently compromised by the emergence of drug-resistant tumor cells. We therefore examined whether loss of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) supports the resistant phenotype by altering redox control and the cellular threshold for ferroptotic injury. Methods: The Gene Expression Omnibus (GEO) datasets GSE172002 and GSE236654 were analyzed to identify resistance-associated pathways. cGAS was depleted in parental cells and restored in resistant derivatives, followed by phenotypic, redox, mitochondrial, and signaling assessments in cultured cells and xenografts; pathway relationships were further examined by rescue experiments and structural modeling. Results: Bioinformatics analysis indicated significant alteration of DNA repair-related pathways in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-resistant models. Resistant PC-9/GR and H1975/OR cells displayed increased half-maximal inhibitory concentration (IC50) values and attenuated inhibition of phosphorylated EGFR (p-EGFR), Phosphorylated Protein Kinase B1 (p-AKT1), and phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) after matched EGFR-TKI treatment. In parental cells, EGFR-TKI exposure was associated with increased DNA damage, cytosolic double-stranded DNA (dsDNA) accumulation, cGAS induction, ferroptosis-related staining patterns, reduced glutathione (GSH), and increased malondialdehyde (MDA), whereas these changes were less evident in resistant cells and were partly attenuated by Ferrostatin-1. Functionally, cGAS knockdown was associated with enhanced proliferative, migratory/invasive, and xenograft growth phenotypes, together with a redox pattern consistent with reduced ferroptosis susceptibility. Conversely, cGAS overexpression in resistant cells produced opposite effects. Altering cGAS abundance redistributed total and Ser40-phosphorylated nuclear factor erythroid 2–related factor 2 (Nrf2) between cellular compartments and concurrently changed sirtuin 3 (SIRT3) abundance and deacetylase activity. Nrf2 or SIRT3 manipulation partially reversed cGAS-associated phenotypes. Conclusions: These findings identify low cGAS abundance as a feature of the resistant state and support its involvement in an Nrf2–SIRT3-dependent antioxidant program that raises the threshold for ferroptotic damage.

Read PDF

Similar papers

Oct 2026

Epidermal growth factor receptor activation is associated with NSCLC cells resistance to ferroptosis and correlates with ROS-NRF2-GCLC/GCLM pathway activation.

Mutations of epidermal growth factor receptor (EGFR) closely correlate with differential ferroptosis sensitivity in select cell lines, but the underlying mechanism is poorly understood. In this study, we identified the epidermal growth factor (EGF)-activated EGFR as a correlate of ferroptosis suppression in non-small c...

Li Wang, Yu-Qing Wang, Yuan Li et al. · 0 citations
Open access Aug 2026

Epigenetically driven GAS2L3 enforces non-canonical cell cycle progression to promote osimertinib resistance in lung adenocarcinoma

These results uncover a metabolism-epigenetics–cell cycle interface that may represent a therapeutic vulnerability in EGFR-mutant LUAD and identify a glycolysis–H4K8la–GAS2L3 axis that drives noncanonical cell-cycle reprogramming independently of classical Cyclin–CDK activation, thereby promoting acquired osimertinib r...

Shu-Man Zhen, Xiaohui Bai, Shu-Tang Liu et al. · 0 citations
Open access Sep 2026

NFS1 activates PI3K/AKT/mTOR signaling to upregulate GPX4 expression and enhance ferroptosis resistance in osteosarcoma

It is suggested that NFS1 functions as an oncogenic driver, as well as a promising prognostic biomarker and therapeutic target in osteosarcoma, and linking metabolic reprogramming to ferroptosis resistance, is suggested.

Yu-Nan Man, Jing-Tang Li, Tao Zhang et al. · 0 citations
Sep 2026

UBR5-KDM5A axis rewires redox metabolism to confer cisplatin resistance in triple-negative breast cancer via the cAMP-PKA-SIRT3 cascade.

These findings establish the UBR5-KDM5A-cAMP-PKA-SIRT3 axis as a central regulator of cisplatin resistance in TNBC and highlight KDM5A as a promising therapeutic target for combination treatment strategies.

Ming-Kai Gong, Fan Liang, Hu Wang et al. · 0 citations
Open access Sep 2026

A four-gene signature identifies TKI-induced persister cells and uncovers a ZLN005-induced pyroptotic vulnerability via the GSDME pathway in EGFR-mutant lung cancer

Public transcriptomic datasets from tumour cell-based models treated with EGFR inhibitors or other targeted agents within the receptor tyrosine kinase (RTK)/RAS/MAPK pathway were integrated with machine-learning-based feature selection, survival analysis and Cancer Dependency Map-based pharmacogenomic screening to defi...

Wen-Wen Chang, Jia-Xin Yuan, Hui-Lin Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.